Tadeu Lima Montagnoli
Instituição:
Universidade Federal do Rio de Janeiro
Centro:
Centro de Ciências da Saúde
Unidade:
Instituto de Ciências Biomédicas
Departamento:
Técnico Administrativos/ICB
Formação:
-
Universidade Federal do Rio de Janeiro
Ciências Biológicas (Farmacologia e Química Medicinal) | Doutorado | 2018 - 2023
-
Universidade Federal do Rio de Janeiro
Engenharia Química | Graduação | 2009 - 2018
-
Instituto Federal de Educação, Ciência e Tecnologia do Rio de Janeiro
| Ensino Profissional de nível técnico | 2005 - 2008
Laboratórios:
Nuvens de Palavras:
Artigos:
(100.00% artigos com DOI)
| Titulo | DOI | Ano |
|---|---|---|
| Molecular hybridization: a powerful tool for multitarget drug discovery | 10.1080/17460441.2024.2322990 | 2024 |
| Antihypertensive Effect of New Agonist of Adenosine Receptor in Spontaneously Hypertensive Rats | 10.36660/abc.20230405 | 2024 |
| Therapeutic Perspectives on ROCK Inhibition for Cerebral Cavernous Malformations | 10.3390/kinasesphosphatases1010006 | 2023 |
| Antinociceptive Effect of the Combination of a Novel α4β2* Agonist with Donepezil in a Chronic Pain Model | 10.3390/biomedicines11123249 | 2023 |
| Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy | 10.3390/cells11020240 | 2022 |
| Novel p38 Mitogen-Activated Protein Kinase Inhibitor Reverses Hypoxia-Induced Pulmonary Arterial Hypertension in Rats | 10.3390/ph15070900 | 2022 |
| Diabetes-Induced Cardiac Autonomic Neuropathy: Impact on Heart Function and Prognosis | 10.3390/biomedicines10123258 | 2022 |
| Estrogen Receptors: Therapeutic Perspectives for the Treatment of Cardiac Dysfunction after Myocardial Infarction | 10.3390/ijms22020525 | 2021 |
| Antinociceptive Effect of Lodenafil Carbonate in Rodent Models of Inflammatory Pain and Spinal Nerve Ligation-Induced Neuropathic Pain | 10.2147/jpr.s295265 | 2021 |
| ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension | 10.3390/cells10071648 | 2021 |
New Benzofuran N-Acylhydrazone Reduces Cardiovascular Dysfunction in Obese Rats by Blocking TNF-Alpha Synthesis |
10.2147/dddt.s258459 | 2020 |
| Therapeutic Benefit of the Association of Lodenafil with Mesenchymal Stem Cells on Hypoxia-induced Pulmonary Hypertension in Rats | 10.3390/cells9092120 | 2020 |
| Reduction of cardiac and renal dysfunction by new inhibitor of DPP4 in diabetic rats | 10.1016/j.pharep.2019.07.005 | 2019 |
| Cardioprotection Induced by Activation of GPER in Ovariectomized Rats With Pulmonary Hypertension | 10.1093/gerona/gly068 | 2018 |
| Human Mesenchymal Stem Cell Therapy Reverses Su5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Mice | 10.3389/fphar.2018.01395 | 2018 |
| Activation of GPER ameliorates experimental pulmonary hypertension in male rats | 10.1016/j.ejps.2016.11.009 | 2017 |
| Treatment with Adenosine Receptor Agonist Ameliorates Pain Induced by Acute and Chronic Inflammation | 10.1124/jpet.115.231241 | 2016 |
| N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity | 10.1016/j.ijcard.2014.02.022 | 2014 |
| Beneficial effects of a novel agonist of the adenosine A 2A receptor on monocrotaline-induced pulmonary hypertension in rats | 10.1111/bph.12193 | 2013 |
Eventos:
(8.00% eventos com DOI)
| Titulo | DOI | Ano |
|---|---|---|
| New sulphonohydrazone ROCK inhibitor improves ventricular function and vascular remodelling in pulmonary hypertension | 2023 | |
| New Agonist Of A2a Adenosine Receptor Improves Cardiac And Vascular Remodeling Induced By Pulmonary Hypertension In Rats | 2023 | |
| Stem cell therapy and activation of adenosine receptor reduce vascular resistance, cardiac dysfunction and remodelling in pulmonary arterial hypertension | 2023 | |
| New acylhydrazone derivatives reduce inflammatory process and cardiac remodeling induced by myocardial infarction | 2023 | |
| Cardiovascular effect of new N-acylhydrazonic derivatives in rats | 2023 | |
| New Rock Inhibitor Improves Pulmonary Vascular Resistance And Right Ventricle Function In Animal Model Of Pulmonary Arterial Hypertension | 2023 | |
| Heart Failure In Menopause: Treatment With Rock Inhibitor And Atorvastatin | 2023 | |
| Evaluation Of Novel A3 Adenosine Receptor Agonist In Hypertension | 2023 | |
| NEW RHO KINASE INHIBITOR ATTENUATES NEUROPATHIC PAIN IN DIABETIC RATS | 2023 | |
| Pharmacological evaluation of a new agonist of adenosine A2a receptor on pulmonary hypertension in rats | 2023 | |
| FASUDIL: IMPROVEMENT OF VENTRICULAR DYSFUNCTION ON ESTROGEN DEPLETION MODEL | 2023 | |
| Novos inibidores de Rho-cinase reduzem disfunção cardíaca e remodelamento vascular em ratos com hipertensão pulmonar | 2022 | |
| New ROCK inhibitor improves cardiovascular function and pulmonary artery remodeling in pulmonary arterial hypertension | 2022 | |
| Activation of adenosine receptor reduces inflammatory process and cardiac remodeling induced by myocardial infarction | 2022 | |
| Reduction of cardiac and vascular remodeling in pulmonary hypertension induced by agonist of A2A adenosine receptor | 2022 | |
| Synthesis and ADME characterization of new sulfonylhydrazones designed as Rho kinase inhibitors for treatment of cardiovascular diseases | 2022 | |
| Activation of adenosine receptors improved cardiac dysfunction induced by myocardial infarction | 2021 | |
| Synthesis of newly substituted isoquinolinesulfonylhydrazones designed as Rho kinase inhibitors for treatment of heart failure and pulmonary hypertension | 2020 | |
| Association of human mesenchymal stem cell and lodenafil in hypoxia-induced pulmonary arterial hypertension | 2020 | |
| Pulmonary hypertension: reduction of vascular and cardiac remodeling by a new inhibitor of p38-alpha MAPK | 2020 | |
| New Rho-kinase inhibitors reduce cardiac dysfunction and vascular remodeling in pulmonary hypertension in rats | 2020 | |
| New DPP-4 inhibitor attenuates metabolic disturbance and improves cardiovascular function in Zucker diabetic fatty fat | 2019 | |
| Pharmacological profile of new adenosine receptor agonist in rats submitted to experimental myocardial infarction | 2019 | |
| Novo inibidor de ROCK reduz disfunção cardíaca e vascular induzida pela hipertensão pulmonar em ratos | 2019 | |
| A novel p38-alpha MAPK inhibitor (LASSBio-1824) reverses SU5416/hypoxia-induced pulmonary arterial hypertension in rats | 2019 | |
| Combination of lodenafil and human menschymal cells therapy reduces cardiac and vascular dysfunction in SU5416/hypoxia-induced pulmonary arterial hypertension in rats | 2019 | |
| Melhora do remodelamento cardíaco induzido pelo infarto agudo do miocárdio pela ativação de receptores de adenosina | 2019 | |
| Agonist of adenosine receptor improves ventricular dysfunction after myocardial infarction via inhibition of cardiac fibroblasts | 10.1161/circ.140.suppl_1.15978 | 2019 |
| New inhibitor of p38-alpha MAPK ameliorates pulmonary hypertension induced by Sugen/hypoxia in rats | 10.1161/circ.140.suppl_1.14909 | 2019 |
| Combination of cholinergic receptor agonist (alpha4-beta2) with cholinesterase inhibitor improves hyperalgesia in chronic pain model | 2019 | |
| Eficácia antinociceptiva da interação de um novo agonista do receptor alfa4beta2 com uma anticolinesterásico central em modelos de dor aguda e crônica | 2019 | |
| Improvement of inflammatory-induced pain and joint damage by novel N-acylhydrazone derivative (LASSBio-1027) in murine models | 2018 | |
| A novel p38-alpha MAPK inhibitor (LASSBio-1824) reverses Sugen/hypoxia-induced pulmonary arterial hypertension in rats | 2018 | |
| New agonist of adenosine receptor (LASSBio-1027) improves cardiac remodeling induced by myocardial infarction | 2018 | |
| Novo agonista do receptor de adenosina (LASSBio-1027) melhora o remodelamento cardíaco após infarto agudo do miocárdio | 2018 | |
| Reduction of pain and joint damage by a novel agonist of adenosine receptor in monoarthritis model | 2018 | |
| Human mesenchymal stem cell therapy reverses Sugen5416/hypoxia-induced pulmonary arterial hypertension in mice | 2018 | |
| A novel p38-alpha MAPK inhibitor (LASSBio-1824) reverses Sugen/hypoxia-induced pulmonary arterial hypertension in rats | 2018 | |
| New ROCK inhibitor reduced vascular dysfunction and cardiac hypertrophy induced by pulmonary hypertension | 2018 | |
| Cardiac remodeling in acute myocardial infarction decreases with new agonist adenosine receptor (LASSBio-1027) | 2018 | |
| A novel p38-alpha MAPK inhibitor reverses Sugen/hypoxia-induced pulmonary arterial hypertension in rats | 10.1161/circ.138.suppl_1.16678 | 2018 |
| Novo agente anti-TNF-alpha melhora edema e hiperalgesia em modelo de monoartrite em camundongos | 2018 | |
| Remodelamento cardíaco no infarto agudo do miocárdio diminui com novo agonista de receptor de adenosina (LASSBIO-1027) | 2018 | |
| Activation of a new estrogen receptor (GPER) ameliorates cardiopulmonary dysfunction in female rats with pulmonary hypertension. | 2017 | |
| Pharmacological evaluation of the agonists of nuclear and G protein coupled estrogen receptors in arterial hypertension associated with estrogen depletion | 2017 | |
| Reversão da hipertensão arterial pulmonar induzida pela monocrotalina em ratos pela lodenafila, inibidor da enzima fosfodiesterase-5 | 2017 | |
| Human mesenchymal stem cell therapy reverses Sugen5416/hypoxia-induced pulmonary arterial hypertension in mice | 2017 | |
| Human mesenchymal stem cell therapy reverses Sugen/hypoxia-induced pulmonary arterial hypertension in mice | 10.1161/circ.136.suppl_1.17314 | 2017 |
| Redução da disfunção endotelial e cardíaca após tratamento com derivado N-acilhidrazônico em ratos espontaneamente hipertensos submetidos ao infarto do miocárdio | 2012 | |
| Correlação da evolução da fibrose com eventos patológicos em biópsias de pacientes transplantados renais | 2009 |